Category: psychiatry

Journal retracts — and republishes — small study on gamma rays for OCD

Screen Shot 2015-10-28 at 8.40.00 PMJAMA Psychiatry has retracted and republished a paper on a cutting-edge procedure for patients with obsessive compulsive disorder.

In the original paper, the authors claimed that three out of eight patients who underwent a procedure that used gamma rays to kill brain cells showed improvements 12 months later (versus zero in the group who underwent a “sham” procedure). But after a reader noticed an “inadvertent” error in the calculation of how many patients had improved, the authors realized that only two of the patients had responded meaningfully to the procedure.

The new results “did not reach statistical significance,” the authors write in a “Notice of Retraction and Replacement.”  JAMA Psychiatry published it yesterday, along with a new version of the article, a letter from psychiatrist Christopher Baethge pointing out the error, and an editorial. The original article is available in the supplemental material of the new version, with the errors highlighted.

Here’s the note in full for “Gamma ventral capsulotomy for obsessive-compulsive disorder: a randomized clinical trial,” which explains the error:

Continue reading Journal retracts — and republishes — small study on gamma rays for OCD

Journal mistakenly publishes Parkinson’s case report twice

Journal of Movement Disorders

A journal has retracted a duplicate version of a case report about a patient with Parkinson’s disease after mistakenly publishing the paper twice.

The Journal of Movement Disorders initially published the report — which detailed the case of an elderly woman with Parkinson’s disease whose symptoms worsened during drug treatment — in 2010. But it ended up printing it again in 2011 because of “a mistake of the editorial office and the publisher.”

The notice reads:

Continue reading Journal mistakenly publishes Parkinson’s case report twice

Investigation finds “careless data workup” in alcoholism drug paper

S00142999

An investigation at Karolinska Institute has led to the retraction of a paper about drug treatments for alcoholics, after concluding the article contains a “very careless data workup.”

The paper, “Memantine enhances the inhibitory effects of naltrexone on ethanol consumption,” found that the drug memantine (normally used to treat Alzheimer’s) enhances the effects of naltrexone in rats, which blocks the high of alcohol.  It was published in the European Journal of Pharmacology and has been cited 10 times, according to Thomson Scientific’s Web of Knowledge.

However, its conclusion is now “unreliable,” according to the retraction note:

Continue reading Investigation finds “careless data workup” in alcoholism drug paper

Re-analysis of controversial Paxil study shows drug “ineffective and unsafe” for teens

downloadThe antidepressant Paxil isn’t safe or effective for teens after all, says a re-analysis of a 2001 study published today in The BMJ.

The original 2001 paper in Journal of the American Academy of Child and Adolescent Psychiatry — study 329, as it’s known — helped greenlight use of the drug (generically known as paroxetine) in young people. But it’s faced accusations of ghostwriting, undisclosed conflicts of interest, and issues with data analysis since publication.

According to a BMJ feature, also published today: Continue reading Re-analysis of controversial Paxil study shows drug “ineffective and unsafe” for teens

“Our manuscript unintentionally failed to meet academic and publication standards”

homeHeaderTitleImage_en_US

Authors of a 2014 review paper about the use of “as needed” medications by people with mental health diagnoses are retracting it, but we’re scratching our heads as to why.

The retraction appears in “The experiences of mental health professionals’ and patients’ use of pro re nata (PRN) medication in acute adult mental health care settings: a systematic review protocol of qualitative evidence,” published by The JBI Database of Systematic Reviews and Implementation Reports.

From the abstract of the paper:

Pro re nata is a Latin phrase meaning “for an unforseen need or contingency”…The authors of the systematic review found that although the practice of using “as required” medication is common there is no good evidence of whether this is the best way of helping people to be less agitated when compared to being given a regular dose of medication.

We’re not entirely sure what went wrong here. This is the full contents of the note:

Continue reading “Our manuscript unintentionally failed to meet academic and publication standards”

A mess: PLOS mistakenly publishes rejected ADHD-herbicide paper, retracts it

logoPLOS One has retracted a paper that links the most commonly used herbicide to ADHD, after it was “published in error.”

According to the note, the paper was “editorially rejected following peer review and consultation with the Editorial Board,” but ended up going through the production process anyway.

When we contacted the authors, they filled us in with more details.

Continue reading A mess: PLOS mistakenly publishes rejected ADHD-herbicide paper, retracts it

Former Wake Forest grad student fudged data for drug study

blaylock
Brandi Blaylock

A former graduate student at Wake Forest School of Medicine “presented falsified and/or fabricated data” in a government-funded drug study, according to findings released by the U.S. Office of Research Integrity earlier today.

The report was released in the wake of an investigation conducted by the university and the ORI. Investigators found that although Brandi Blaylock recorded responses of a dozen laboratory monkeys after giving them anti-abuse drugs, she hadn’t given them the compounds “per protocol.”

Blaylock then presented the data at “two poster presentations, several laboratory meetings, and progress reports.”

Some of her research was supported by a grant from the National Institute of Drug Abuse, “Dopamine D2 Receptors In Primate Models of Cocaine Abuse,” which examined the effects of novel dopamine D3 receptor compounds on drug addiction on monkeys.

However, according to the report, Blaylock presented the falsified responses from a dozen monkeys: Continue reading Former Wake Forest grad student fudged data for drug study

Drugmaker accused of omitting side effect data from 2003 Risperdal paper

cover7607A 2003 paper may have left out potentially “significant” data on the long-term side-effects of an antipsychotic drug used in children, according to a former head of the U.S. Food and Drug Administration.

As reported by the Toronto Star, David Kessler is alleging that Janssen, the maker of Risperdal (and owned by Johnson & Johnson), omitted data about the risks of the drug: In particular, that boys who use it over a long period may be at risk of growing breasts.

There’s anecdotal evidence of the side effect. One family claimed the drug had caused their son to grow a pair of 46 DD-sized breasts in a lawsuit against Johnson & Johnson, reported the Wall Street Journal in February. They won, to the tune of $2.5 million. The suit is apparently just one of 1,200 like it.

The abstract of the paper, “Prolactin levels during long-term risperidone treatment in children and adolescents,” published in The Journal of Clinical Psychiatry, suggests that levels of a key hormone aren’t a problem in the long term:

Continue reading Drugmaker accused of omitting side effect data from 2003 Risperdal paper

Psych paper falls afoul of journal’s plagiarism policy (hint: don’t plagiarize)

jcpharmacopharmThe Journal of Clinical Psychopharmacology has retracted a 2011 paper on depersonalization disorder by a pair of authors in Azerbaijan who got a bit too familiar with their source material without proper attribution. And the journal has offered its readers a handy — if depressingly obvious — admonition about publication ethics.

The article, “Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity. Randomized, double-blind, placebo-controlled study,” by researchers at the Central Mental Clinic for Outpatients of Baku City, purported to find that: Continue reading Psych paper falls afoul of journal’s plagiarism policy (hint: don’t plagiarize)

Retraction appears for psychiatrist sought for arrest in alleged fraud scheme

malafosse
Alain Malafosse, via University of Geneva

Want bogus data, million-dollar fraud allegations and a scientist on the lam? We give you Alain Malafosse.

The British Journal of Psychiatry has retracted a June 2013 paper by Malafosse and his colleagues on the genetics of bipolar disorder in children because Malafosse allegedly fabricated key data in the study.

The article, “Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder,” purported to find that people with bipolar disorder who had experienced more, and more severe, abuse early in life were more likely to show epigenetic changes. According to the abstract:

Continue reading Retraction appears for psychiatrist sought for arrest in alleged fraud scheme